NCT03938987 2026-02-09
ACIT001/EXC002
University of Alberta
Phase 1/2 Recruiting
Clinical Trials
7 trialsNCT04545762 2026-01-14
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
University of California, San Francisco
Phase 1 Recruiting
NCT05621096 2025-09-25
Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma
University of Nebraska
Phase 1 Active not recruiting
NCT04089215 2023-11-24
CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma
Shanghai Ming Ju Biotechnology Co., Ltd.
Phase 2 Unknown
NCT04718883 2023-11-24
CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma
Shanghai Ming Ju Biotechnology Co., Ltd.
Phase 2 Active not recruiting
NCT02659943 2023-04-19
T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT04160195 2022-02-15
T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated